New Four-Pronged antibody takes on advanced breast cancer

NCT ID NCT05160545

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called GNC-035, a tetra-specific antibody designed to attack breast cancer cells in multiple ways. It involves 36 adults with locally advanced or metastatic breast cancer whose disease has worsened after standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GNC-035 (a tetra-specific antibody given by IV infusion)
What this could lead to: If this works, it could point toward a new treatment option for advanced breast cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 36 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Dongguan People's Hospital

Dongguan, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510120, China
The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China
The Third Hospital of Changsha

Changsha, Hunan, China
West China Hospital，Sichuan University

Chengdu, Sichuan, China
ZhuJiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.